Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132205 | 1.00 | TPMT (0.54) | TPMTALDH1A1MAPK1AOX1HPGD | |
| SCHEMBL5155052 | 0.86 | ALDH1A1 (0.57) | ALDH1A1AOX1HPGDTDP1TRIM24 | |
| SCHEMBL2588646 | 0.86 | MAPT (0.55) | TPMTALDH1A1MAPK1HPGDMAPT | |
| SCHEMBL3637463 | 0.79 | CA1 (0.55) | ALDH1A1AOX1HPGDTDP1TRIM24 | |
| SCHEMBL29361496 | 0.79 | ALDH1A1 (0.59) | TPMTALDH1A1MAPK1AOX1HPGD | |
| SCHEMBL1050289 | 0.79 | ALDH1A1 (0.59) | TPMTALDH1A1MAPK1AOX1HPGD | |
| SCHEMBL6291227 | 0.79 | SRC (0.53) | ALDH1A1AOX1HPGDTDP1TRIM24 | |
| SCHEMBL30122857 | 0.79 | ALDH1A1 (0.63) | ALDH1A1MAPK1HPGDMAPTTDP1 | |
| SCHEMBL524712 | 0.79 | ALDH1A1 (0.63) | ALDH1A1MAPK1HPGDMAPTTDP1 | |
| SCHEMBL12552993 | 0.79 | SRC (0.49) | TPMTALDH1A1MAPK1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094561-A | Liquid fertilizer ready-to-use agrochemical formulation | — | 2026-05-26 | — | — | CN | disclosed |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3898595-B1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3898595-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | Merck Sharp & Dohme Corp. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113423695-A | Pyrimidinone derivatives as selective cytotoxic agents against HIV infected cells | 默沙东公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020131597-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| CN-101679324-B | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2012-10-03 | — | — | CN | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| CN-101679324-A | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2010-03-24 | — | — | CN | disclosed |
| US-7196108-B2 | Bicyclic heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1487446-A4 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1487446-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003075858-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | TPMT 1440/4885ALDH1A1 2202/4885MAPK1 785/4885 |
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | TYMP, PNP, CD4 | TPMT 95/4885ALDH1A1 2371/4885MAPK1 976/4885 |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | PC, CYP27A1, GPR119 | TPMT 1796/4885ALDH1A1 607/4885MAPK1 2024/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | TPMT 95/4885ALDH1A1 2371/4885MAPK1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.